SECUKINUMAB belongs to the class of monoclonal antibodies. It is primarily indicated for the treatment of moderate to severe plaque psoriasis in patients six years and older who are candidates for systemic therapy or phototherapy, active psoriatic arthritis (PsA) in patients two years and older; adults with active ankylosing spondylitis (AS), adults with active non-radiographic axial spondyloarthritis (nr-axSpA).
SECUKINUMAB consists of Secukinumab. It works by inhibiting the release of inflammatory cytokines and chemokines that contribute to autoimmune and inflammatory diseases.
SECUKINUMAB is a parenteral medicine. A trained healthcare professional will administer it. Hence, do not self-administer. SECUKINUMAB may cause side effects such as mild nose and throat infection, diarrhoea, upper respiratory tract infection, and injection site reactions. These side effects do not require medical attention or resolve over time.
Before taking SECUKINUMAB, inform your doctor about all your allergic or hypersensitivity reactions to medicines or food. Also, tell your doctor about your medical history and other medications you are currently taking to rule out any potential negative effects. Secukinumab is not recommended if you are pregnant. If you become pregnant while taking secukinumab, notify your healthcare professional immediately. Breastfeeding mothers should inform the physician whether to stop or nurse the child while on treatment.
Moderate to severe plaque psoriasis, Active psoriatic arthritis, Active ankylosing spondylitis, Active non-radiographic axial spondyloarthritis.
SECUKINUMAB consists of Secukinumab, which belongs to the class of monoclonal antibodies. SECUKINUMAB binds to the interleukin-17A cytokine and inhibits the interaction with the IL-17 receptor. In simple terms, it inhibits the release of inflammatory cytokines and chemokines that contribute to autoimmune and inflammatory diseases. This helps reduce inflammation and pain, redness, and inflammation (swelling) caused by various autoimmune diseases.
Before taking SECUKINUMAB, inform your doctor about all your allergic or hypersensitivity reactions to medicines or food. Also, tell your doctor about your medical history and other medications you are currently taking to rule out any potential negative effects. SECUKINUMAB is not recommended in populations with serious infections, hypersensitivity reactions, Tuberculosis (TB), inflammatory bowel disease, and Eczematous Eruptions (skin reactions). So, inform your healthcare professional about all your medical conditions and any allergic reactions to food or medications. Do not take any vaccinations, especially live while on therapy with this medicine. SECUKINUMAB is not recommended if you are pregnant. If you become pregnant while taking secukinumab, notify your healthcare professional immediately. A breastfeeding mother should inform the physician whether to stop or nurse the child while on treatment.
Drug-Drug Interactions: SECUKINUMAB may interact with other immunosuppressants (e.g. adalimumab, certolizumab), immunomodulating medication (e.g. fingolimod), antirheumatic drug (e.g. leflunomide), and vaccines (e.g. BCG vaccine, dengue vaccine)
Drug-Food Interactions: No interactions found.
Drug-Disease Interactions: SECUKINUMAB interacts with disease conditions, including infections (bacterial/fungal/protozoal/viral), Tuberculosis (TB), and inflammatory bowel disease.
It is not known if alcohol interacts with SECUKINUMAB. Please consult your doctor.
If you are pregnant or planning to be pregnant, inform your doctor before receiving SECUKINUMAB. Your doctor may prescribe this medicine if the benefits outweigh the risks.
It is not known whether SECUKINUMAB passes into human milk. Hence, if breastfeeding, inform your doctor before receiving SECUKINUMAB. Your doctor may advise you to stop breastfeeding for a certain period.
SECUKINUMAB will be administered in the hospital setting. Hence, driving and operating machines is not recommended.
Inform your doctor before receiving the SECUKINUMAB if you have any history of liver disease. Your doctor will prescribe only if the benefits outweigh the risks.
If you have a history of kidney disease, let your doctor know before receiving the SECUKINUMAB. Your doctor will prescribe only if the benefits outweigh the risks.
The use of SECUKINUMAB in pediatric patients is safe if prescribed by the paediatrician. The doctor will administer the dose based on the condition of your children.
Plaque psoriasis: Plaque psoriasis is a most common autoimmune condition in which skin cells multiply faster than normal, resulting in white scales and itchy, red, dry patches. Certain medications, infections, skin injury, stress, and tobacco or alcohol use are the common triggers for plaque psoriasis.
Psoriatic arthritis: It is a type of inflammatory arthritis which occurs in patients with psoriasis. It could also occur in patients without psoriasis, particularly in those with a family history of psoriasis. It affects large joints in the lower extremities, the distal joints of toes and fingers, and the back and pelvis. Symptoms include inflammation of joints, difficulty moving, swelling, patches of red, scaly skin, and pain.
Ankylosing spondylitis: It causes pain and stiffness in the spine. The pain generally starts in the lower back and can spread to the neck, damaged joints, or other body parts. Ankylosing spondylitis symptoms include decreased flexibility, which usually leads to a hunched-forward posture and pain in the back and joints.
Active non-radiographic axial spondyloarthritis: It is a persistent inflammatory disorder. It is characterized by active inflammation of the spine and sacroiliac (SI) joints, which connect the lower spine and pelvis.
Scapho 150Mg/Ml Inj
₹17000 (MRP 20000)15%Off